Last reviewed · How we verify

Lidocaine 7% + Tetracaine 7% cream

Galderma R&D · FDA-approved active Small molecule

Lidocaine 7% + Tetracaine 7% cream is a Local anesthetic combination Small molecule drug developed by Galderma R&D. It is currently FDA-approved for Topical anesthesia for dermatological procedures (e.g., laser treatment, chemical peels, microdermabrasion), Numbing prior to minor surgical procedures on skin.

Lidocaine and tetracaine are local anesthetics that block sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce topical anesthesia.

Lidocaine and tetracaine are local anesthetics that block sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce topical anesthesia. Used for Topical anesthesia for dermatological procedures (e.g., laser treatment, minor surgical procedures), Numbing cream for skin procedures requiring local anesthesia.

At a glance

Generic nameLidocaine 7% + Tetracaine 7% cream
SponsorGalderma R&D
Drug classLocal anesthetic combination
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaDermatology / Pain Management
PhaseFDA-approved

Mechanism of action

Both lidocaine and tetracaine are amide and ester local anesthetics, respectively, that work by inhibiting sodium influx through voltage-gated sodium channels in nerve fibers. This prevents depolarization and action potential propagation, resulting in reversible loss of sensation in the applied area. The combination formulation provides rapid onset (lidocaine) and prolonged duration (tetracaine) of topical anesthesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lidocaine 7% + Tetracaine 7% cream

What is Lidocaine 7% + Tetracaine 7% cream?

Lidocaine 7% + Tetracaine 7% cream is a Local anesthetic combination drug developed by Galderma R&D, indicated for Topical anesthesia for dermatological procedures (e.g., laser treatment, chemical peels, microdermabrasion), Numbing prior to minor surgical procedures on skin.

How does Lidocaine 7% + Tetracaine 7% cream work?

Lidocaine and tetracaine are local anesthetics that block sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce topical anesthesia.

What is Lidocaine 7% + Tetracaine 7% cream used for?

Lidocaine 7% + Tetracaine 7% cream is indicated for Topical anesthesia for dermatological procedures (e.g., laser treatment, chemical peels, microdermabrasion), Numbing prior to minor surgical procedures on skin.

Who makes Lidocaine 7% + Tetracaine 7% cream?

Lidocaine 7% + Tetracaine 7% cream is developed and marketed by Galderma R&D (see full Galderma R&D pipeline at /company/galderma-r-d).

What drug class is Lidocaine 7% + Tetracaine 7% cream in?

Lidocaine 7% + Tetracaine 7% cream belongs to the Local anesthetic combination class. See all Local anesthetic combination drugs at /class/local-anesthetic-combination.

What development phase is Lidocaine 7% + Tetracaine 7% cream in?

Lidocaine 7% + Tetracaine 7% cream is FDA-approved (marketed).

What are the side effects of Lidocaine 7% + Tetracaine 7% cream?

Common side effects of Lidocaine 7% + Tetracaine 7% cream include Erythema, Edema, Blanching, Contact dermatitis, Transient burning or stinging.

What does Lidocaine 7% + Tetracaine 7% cream target?

Lidocaine 7% + Tetracaine 7% cream targets Voltage-gated sodium channels and is a Local anesthetic combination.

Related